"Benzeneacetamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds based on benzeneacetamide, that are similar in structure to ACETANILIDES.
| Descriptor ID |
D044482
|
| MeSH Number(s) |
D02.065.064.294 D02.455.426.559.389.048
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzeneacetamides".
Below are MeSH descriptors whose meaning is more specific than "Benzeneacetamides".
This graph shows the total number of publications written about "Benzeneacetamides" by people in this website by year, and whether "Benzeneacetamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzeneacetamides" by people in Profiles.
-
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer. 2024 Oct; 5(10):1515-1533.
-
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Adv. 2024 05 14; 8(9):2312-2325.
-
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations. Lung Cancer. 2024 04; 190:107512.
-
Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities. Prostate. 2021 09; 81(12):799-811.
-
Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. Cancer Lett. 2021 04 01; 502:180-188.
-
GLS2 is protumorigenic in breast cancers. Oncogene. 2020 01; 39(3):690-702.
-
Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia. Mol Cancer Ther. 2019 11; 18(11):1937-1946.
-
Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer. Sci Rep. 2017 11 23; 7(1):16159.
-
Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies. Ophthalmology. 2017 06; 124(6):776-785.
-
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget. 2016 Nov 29; 7(48):79722-79735.